Editor’s note: The SMA News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Treatment with Evrysdi (risdiplam) is safe and increases the levels of SMN — the missing protein in spinal muscular…
PTC Therapeutics and the Spinal Muscle Atrophy (SMA) Association will collaborate in funding research into regenerative medicine, and into SMA in particular. With the advent of disease-modifying SMA therapies such as Evrysdi (risdiplam) and Spinraza (nusinersen), regenerative medicine — which aims to restore damage caused by…
Eight weeks of treatment with investigational add-on oral therapy reldesemtiv safely improved motor and respiratory strength in adolescents and adults with spinal muscular atrophy (SMA), according to final data from a Phase 2, hypothesis-generating clinical trial. These findings support further clinical testing of reldesemtiv, designed to aid skeletal muscle…
The gene therapy Zolgensma was added to the list of medications available to eligible spinal muscular atrophy (SMA) type 1 patients through England’s and Scotland’s national health services (NHS). With a reported list price of £1.79 million ($2.48 million) per dose — the most expensive yet — Novartis’ Zolgensma uses…
Many diseases have their own awareness color — breast cancer is pink, muscular dystrophy is green, and AIDS is red, for example — but what’s the significance of pink, green, blue, and purple lights side-by-side? These are the colors most often used to represent Rare Disease Day. This…
Adults with spinal muscular atrophy (SMA) usually do not experience weakness or impairment of any sort in the muscles controlling their eye movements, a recent study reported. When such impairments are present, they should prompt physicians to re-evaluate their initial diagnosis and consider the possibility that a patient may…
Being an adolescent or young adult with spinal muscular atrophy (SMA) presents unique challenges, according to a study based on viewpoints expressed by patients ages 12 to 25. “‘I have SMA, SMA doesn’t have me’: a qualitative snapshot into the challenges, successes, and quality of life…
Evrysdi (risdiplam) has been recommended for approval in the European Union (EU) to treat spinal muscular atrophy (SMA) patients, ages 2 months and older, with a clinical diagnosis of type 1, 2, or 3, or with one to four copies of the SMN2 “backup” gene. “Our close partnership…
Genentech’s Evrysdi (risdiplam) improved survival in infants with spinal muscular atrophy (SMA) type 1, and allowed them to achieve developmental milestones not usually seen in the natural course of the disease, according to one-year data from the dose-finding part of the FIREFISH trial. While the trial is still ongoing…
When Josylnn Jones McLaughlin moved to Guangzhou, China, to teach conversational English in 2012, she didn’t expect to bring home two girls, one with spinal muscular atrophy (SMA) and the other with spina bifida, when she returned to Anderson, South Carolina, more than a year later. She certainly…
Get regular updates to your inbox.
